Kornimate/medical-research-clean huggingface dataset:
optimized referral of knee patients at the clinic of sports injuries

Conditions: Knee Injuries; Knee; Injury, Meniscus (Lateral) (Medial)

Summary: the aim of the study is to evaluate an algorithm to screen patients with a possibility of meniscal injury referred to a sports injury outpatient clinic by using patient-reported symptoms. it will be investigated whether the algorithm is able to identify which patients are deemed relevant to undergo assessment by a physician (i.e. in case the patient need to undergo surgery) and which patients are relevant to undergo assessment by a physiotherapist. this will be evaluated by estimating the sensitivity of the new algorithm compared to actual relevancy based on the traditional clinical assessment of the patients.

according to current practice, patients referred to the clinic of sports injuries will be assessed by either a physician or a physiotherapist. current practice will continue unchanged during this study. before the scheduled assessment, patients will be asked to fulfill a questionnaire including koos, a further description of symptoms, previous treatment by physiotherapist and expected upcoming treatment (i.e. surgery or referral to physiotherapist). an algorithm based on the self-reported information will be used to categorize whether the patient are considered relevant to be referred to assessment by a physician or to assessment by a physiotherapist. after clinical assessment of the patient, the physician or physiotherapist does a registration of diagnosis, choice of treatment and complexity. based on choice of treatment and complexity, the patient will be categorized as either relevant to be referred to assessment by a physician or to assessment by a physiotherapist. this categorization is by definition considered correct. the ability of the algorithm will be evaluated by comparing it's categorization to the correct result. sensitivity will be estimated.

Eligibility criteria:
inclusion criteria: * patients above the age of 35 referred to the clinic of sports injuries with knee symptoms exclusion criteria: * cognitive or language problems that precludes the filling of the questionnaires * previous surgery in the knee * symptoms only located in the anterior part of the knee
clinical trial to reduce sedentary lifestyle in patients with type 2 diabetes

Conditions: Type 2 Diabetes; Sedentary Behaviors

Summary: the prevalence of diabetes has increased worldwide, making it the most prevalent metabolic disorder. physical inactivity contributes to the progression of this disease and aggravates other comorbidities, such as obesity and cardiovascular disease. beneficial strategies aimed at promotion and healthy aging, oriented to decrease sedentary behavior, are necessary to obtain desirable metabolic effects and improve the quality of life of people with diabetes. the objective is to examine, through a clinical trial, the effect of decreasing sedentary time and increasing motivation to adopt an active lifestyle on different clinical, anthropometric and biochemical parameters in patients diagnosed with type 2 diabetes mellitus.

a clinical trial with a 12-month follow-up will be carried out. the study has been chosen to be conducted as a single-center study for strategic and logistical reasons. a two-arm parallel design will be used. the control group (cg) will receive messages by mail with healthy lifestyle habits, while the intervention group (ig) will receive a behavioral intervention based on lifestyle modification, focusing on reducing sedentary time. these interventions will be directed by the research nurse. the general objective of the study is to know the effect of decreasing sedentary time and increasing motivation to adopt an active lifestyle of different health-related parameters in patients diagnosed with type 2 diabetes mellitus. also to provide support and resources for the proper management of diabetes. likewise, it will be verified that face-to-face interventions and telephone interventions by nursing professionals decrease the sedentary time in the diabetic population and if it means and improvement in clinical, anthropometric and biochemical parameters. also, to evaluate the quality of life and the degree of motivation aimed at reducing sedentary time and to integrate the reduction of sedentary time in the lifestyle of the participants with practical tools and guidelines adapted to the circumstances.

Eligibility criteria:
inclusion criteria: * diagnosis of type 2 diabetes mellitus * 18 years of age or older * minimal physical fitness exclusion criteria: * medical contraindication * pregnant women * recent surgical interventions limiting mobility * patients currently undergoing oncological treatment or less than one year since the end of treatment. * suffering from dementia, impairment or a severe cognitive or psychiatric disorder.

Keywords: diabetes sedentary lifestyle sedentary behavior quality of life
the relationship between cftr gene mutations and exercise capacity

Conditions: Cystic Fibrosis

Summary: this study will explore the effect of mutation severity on exercise capacity. through a better understanding of the association between mutation severity and exercise capacity, clinicians will be more able to predict a given patient's level of independent functioning based on their genes, which is essential information that patients' families want to know upon diagnosis.

cystic fibrosis (cf) is a disease that disrupts the lungs. with an average survival of 40.7 years, this condition affects around 30,000 in the us. most commonly seen in among those of european descent, cf is present in about 1 in every 2,500 caucasian newborns. a genetic mutation causes a thick and sticky mucus production in the lungs. thus, cf patients are more likely to have respiratory failure and lung infections. these symptoms of cf vary among patients and primarily depend on the severity of the gene mutations.currently, there is not a lot of literature on the relationship between cftr genes and exercise capacity, highlighting the relevance of this study. this study is expected to last at least 10 weeks. participants will be given a fitbit tracker at the beginning of the study to wear during their participation. participants are asked to engage in their normal level of physical activity. no one from the research team will have direct access to their fitbit information. in other words, participants will create an account on the fitbit website and only participants will be able to see the information on there. a weekly survey about their fitbit mileage will be given by a research member via phone. the weekly survey will also ask more opinionated questions, regarding any updates on their attitudes toward exercise. at the conclusion of this 10-week study, participants will have the option of keeping their fitbit tracker. about 50 participants are expected to enroll in this study. at any point of the study, participants will be given the freedom to withdraw their participation.

Eligibility criteria:
inclusion criteria: * cystic fibrosis patient who has been tested positive for a cf mutation of class 1-5. * part of the vcu cystic fibrosis program. * above 18 years old. exclusion criteria: * has not been tested positive for a known cf mutation. * not a part of the vcu cystic fibrosis program. * cannot be under 18 years old.

Keywords: exercise
a phase 2 study for patients with a physician's diagnosis of rheumatoid arthritis

Conditions: Arthritis, Rheumatoid

Summary: the purpose of this study is to determine the effectiveness and safety, over 6 months, of 5 doses of cp-690,550 for the treatment of adults with active rheumatoid arthritis. five out of seven subjects will receive cp-690,550. one out of seven will receive adalimumab (humira®) and one out of seven will only receive inactive substances (placebo.)


Eligibility criteria:
inclusion criteria: * subjects must have active rheumatoid arthritis * subjects must have failed at least 1 disease modifying anti-rheumatic drug (dmard) * subjects must not be currently taking any dmard other than an antimalarial exclusion criteria: * subjects who discontinued any previous tnf inhibitor therapy for either lack of benefit or safety. * subjects who previously received adalimumab (humira®) therapy for any reason. * subjects with evidence of blood disorders, chronic infections or untreated tuberculosis

Keywords: janus kinase 3 clinical trial
prevention with oleanolic acid of insulin resistance

Conditions: Insulin Resistance; Metabolic Syndrome

Summary: oleanolic acid (oa), a triterpene that is highly present in olive leaves, has been proposed as component of functional foods in the prevention of metabolic syndrome due to its anti-inflammatory activity. in this research project we will study the presence of oa in postprandial trl in healthy adolescents and in normal weight. moreover, thp-1 macrophages will be incubated with lps for 48h after pretreatment with oa at different concentrations. also, trl will be isolated from healthy adolescents before and 2 and 5h postprandially after the intake of a meal containing the functional olive oil or common olive oil and incubated with thp-1 macrophages.


Eligibility criteria:
inclusion criteria: -participants without digestive, metabolic or oncologic disorders or any other pathology exclusion criteria: -not having the informed consent signed by the parents
effect of shotblocker and palm stimulator

Conditions: Pain

Summary: this study discusses the advancements in nursing, particularly focusing on intramuscular injections, their complications, and innovative non-pharmacological methods such as the shotblocker and palm stimulator to reduce pain. these methods, based on the gate control theory, aim to minimize discomfort during injections by applying tactile stimulation, which has proven effective in various studies.

it was planned to examine the effect of shot blocker and palm stimulator use on injection-related pain during intramuscular injection.this study is a randomized controlled, single-blind, parallel group experimental study to be conducted in the emergency department of a state hospital in konya, turkey. the research will be conducted on individuals who will receive intramuscular (im) injection. participants will be randomized and divided into shotblocker, palm stimulator and control groups. data collection will run from april 2024 to may 2024 and analyzes will be conducted blinded by an independent statistician. this study aims to evaluate the effects of these techniques on pain and anxiety.

Eligibility criteria:
inclusion criteria: * volunteering to participate in the research, * those who will receive vitamin b injection ordered by physician due to b12 deficiency, * conscious and oriented, * able to understand and speak turkish, * age range is between 18-65, * having no vision or hearing problems, * pain score of 2 or less when evaluated with a visual analog scale, * able to lie in the right lateral position where injection can be administered, * those who have not had an im injection into the right ventrogluteal area in the last week, * body mass index is within the normal range (25.0-29.9 kg/m2) according to who, * those who have not used any analgesics or muscle relaxants in the last 24 hours, * does not have any problems such as hardness, mass, edema or infection in the area to be injected, * according to his own statement, he has no psychiatric diagnosis, exclusion criteria: * having pain anywhere in the body, * narcotic type or different analgesic area before application, * pregnant or suspected of pregnancy, * individuals in menstrual period, * receiving chemotherapy and radiotherapy treatment, * those who have migraine, are in the postoperative period, have nerve damage, neuropathy and a vascular disease, * those who have disabilities in grasping their hands,
plasma dna and vascular remodelling in patients with sickle cell disease

Conditions: Sickle Cell Disease

Summary: the purpose of this study is to evaluate the relationship between plasma dna levels and micro- and macro-circulatory vascular remodelling in patients with sickle cell disease


Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * homozygous ss or sß0 sickle cell disease patients. * seen in consultation for an annual clinical and para-clinical evaluation of his/her disease. * stable clinical condition of the disease defined as the absence of severe vaso-occlusive crises (requiring hospitalisation or a visit to the emergency unit) in the previous month and absence of transfusion in the previous 3 months. exclusion criteria: * other haemoglobinopathy * known diabetes. * recent administration of an anticoagulant treatment at curative doses (\< 48h before inclusion), or platelet-inhibiting drugs (less than 1 week prior to inclusion). * recent transfusion (less than 3 months prior to inclusion). * pregnancy or post-partum (first 40 days after giving birth). * recent consumption of alcohol (less than 10h), coffee (less than 3h), and tobacco (less than 36h) before inclusion. * known infection with hepatitis b, c, and hiv infection. * known cancer or progressive blood disease. * known haemostasis or coagulation disorders. * progressive inflammatory or infectious diseases. * recent history (dating less than 3 months) of venous (pulmonary embolism, deep venous thrombosis) or arterial (acute coronary syndrome, stroke, peripheral arterial ischaemia) thromboembolic event. * adult patients subject to legal protection measures. * patients already involved in a therapeutic protocol. * patients not affiliated to a social security system. * non-inclusion criteria related to the technical requirements of the endo-pat: * known cardiac arrhythmia. * severe raynaud's syndrome. * hand or arm deformity that prevents an endopat analysis.
to assess the pharmacokinetics, safety and tolerability of selumetinib in renal impaired subjects and healthy subjects

Conditions: Solid Tumours

Summary: a study to assess the pharmacokinetics, safety and tolerability of selumetinib (azd6244, arry-142886) in subjects with renal impairment and healthy subjects

an open label study to assess the pharmacokinetics, safety and tolerability of 50 mg single oral dose of selumetinib (azd6244, arry-142886) in subjects with renal impairment and healthy subjects

Eligibility criteria:
inclusion criteria all participants: 1. male and female (non childbearing potential) subjects aged 18 years or more with suitable veins for cannulation or repeated venipuncture. 2. have a weight of at least 50 kg (110 lbs) and body mass index (bmi) between 18 and 40 kg/m2, inclusive. inclusion healthy volunteers only: 3. must be in good health as determined by a medical history, physical examination, 12 lead ecg, clinical laboratory evaluations, and an ophthalmic examination performed before the administration of the investigational product. inclusion renal impaired patients only: 4. stable renal function exclusion criteria all participants: 1. subjects of japanese or non japanese asian ethnicity. 2. any one parent or grandparent (maternal or paternal) is japanese or non-japanese asian (e.g. china, taiwan, korea, philippines, thailand, vietnam and malaysia). asian indians are acceptable. 3. subjects who smoke more than 10 cigarettes or the equivalent in tobacco per day 4. in the opinion of the investigator, any evidence of additional severe or uncontrolled systemic disease (eg, currently unstable or uncompensated hepatic, cardiovascular, or respiratory disease) or laboratory finding, physical examination, hematology, clinical chemistry, urinalysis, vital signs, or 12-lead ecg that makes it undesirable for the subject to participate in the study. exclusion renal impaired patients only: 5. subjects with an active renal transplant (subjects who have previously received a renal transplant and are currently undergoing dialysis due to transplant failure may be enrolled). 6. acute coronary syndrome within 6 months prior to administration of the investigational product.

Keywords: phase i, healthy, pharmacokinetics, renal impairment
therapeutic education program in psoriasis

Conditions: Psoriasis

Summary: the primary objective of this research protocol is to assess the effect of a structured therapeutic education program on the quality of life of patients with moderate to severe psoriasis

psoriasis is a chronic inflammatory skin disease affecting 1 to 3% of the french population. moderate to severe psoriasis has a significant impact on quality of life. psoriasis is associated with an increased risk of depression, social isolation, unemployment. in addition, it has recently be shown that patients with moderate to severe psoriasis have an increased incidence of cardiovascular risk factors such as hypertension, overweight, hyperlipidemia and exposure to tobacco and alcohol. these so-called comorbidites may have a negative impact on psoriasis management. they also may account for the reduced life expectancy reported in patients with severe psoriasis. therapeutic education is a structured process whose objective is to help patients to acquire or to maintain competencies that are required to live with a chronic disease. therapeutic education is an important process to be integrated into the therapeutic strategy. it has to take into account co-morbidities, social and psychological context and its priorities need to be defined with the patient.

Eligibility criteria:
inclusion criteria: * moderate to severe psoriasis defined as patients receiving a systemic psoriasis treatment including methotrexate, cyclosporine, puva, retinoids or a biological agent and with significant impact on quality of life defined as a skindex \> 18 * patients with palmo-plantar or erythrodermic psoriasis may be included if they can be classified as moderate to severe according the above described definitions exclusion criteria: * patients not able to give informed consent, * patients not able to follow the program, * patients without social security affiliation.
evaluation of the effect of rosuvastatin on cisplatin-induced nephrotoxicity and ototoxicity

Conditions: Cisplatin Adverse Reaction

Summary: cisplatin is an effective anti-cancer drug for the treatment of many solid tumors in humans. although the clinical response to cisplatin chemotherapy is encouraging, the nephrotoxicity and ototoxicity of the drug makes it difficult to continue its administration in many cases. cisplatin nephrotoxicity occurs through several mechanisms, mainly through the transport and accumulation of cisplatin into renal epithelial cells, injury to nuclear and mitochondrial dna, activation of multiple cell death pathways and initiation of inflammatory response. accordingly, several experimental strategies were developed to prevent this toxicity. for example, drugs that reduced renal cisplatin accumulation such as organic cation transporter 2 (oct2) and copper transporter (ctr1) inhibitors, antioxidants, antiapoptotic and anti-inflammatory agents were investigated. however, many of these drugs interfered with the cytotoxic effects of cisplatin. statins are agents used for reducing plasma cholesterol through the inhibition of the enzyme 3- hydroxy-3- methylglutaryl coenzyme a (hmg-coa) reductase. in addition, statins are also proven to have pleiotropic, non-lipid dependent effects. these effects include anti-inflammatory actions and reduction of oxidative stress. based on animal studies performed, statins have been shown to reduce the nephrotoxic effects of cisplatin in rats. in addition, ongoing clinical trials are aiming to investigate the role of statins in the protection against the ototoxicity of cisplatin as well. our aim is to assess the protective effect of statins on cisplatin-induced nephrotoxicity and ototoxicity in humans.


Eligibility criteria:
inclusion criteria: * histologically proven lung and breast cancer patients indicated for cisplatin (4-6 cycles) * normal baseline serum creatinine levels * normal baseline audiometry * age between 18-70 years exclusion criteria: * patients with more than one type of cancer * patients with prior chemotherapy treatment * treatment with statins within 12 months before assignment * treatment with fibrates within 4 weeks before assignment * pregnancy and lactation * abnormal liver function tests or blood count

Keywords: cisplatin rosuvastatin nephrotoxicity ototoxicity
study to compare the efficacy and safety of two non-preserved artificial tears for the treatment of dry eye signs and symptoms

Conditions: Dry Eye Syndromes

Summary: to compare the efficacy and safety of two non-preserved artificial tears, (carboxymethylcellulose 0.5%, + glycerin 0.9% vs. sodium hyaluronate 0.18%) eye drops for the treatment of the signs and symptoms of dry eye disease.


Eligibility criteria:
inclusion criteria: * current use of an artificial tear product at least 2 times per day (e.g. for relief of dry eye symptoms of dryness). * be likely to complete the entire course of study and to comply with appropriate instructions exclusion criteria: * have undergone refractive surgery (e.g., cataract surgery, prk, lasik, or any surgery involving a limbal or corneal incision) within the last 12 months. * have uncontrolled systemic disease * are currently using, or have used within 14 days of study enrollment, any ocular medications other than artificial tears * have anticipated contact lens wear during the study * have an active ocular infection